Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline

Therapeutic Drug Monitoring

Volumn 37, Issue 1, 2015, Pages 90-97

  Gjestad, Caroline ^a,b   Westin, Andreas A ^a   Skogvoll, Eirik ^a,c   Spigset, Olav ^a,c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Citalopram; drug interactions; escitalopram; proton pump inhibitor; sertraline

Indexed keywords

CITALOPRAM; ESCITALOPRAM; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; SERTRALINE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; DRUG INTERACTION; HALF LIFE TIME; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CITALOPRAM; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; YOUNG ADULT;

EID: 84922174271     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000101     Document Type: Article

References (30)

1. Yu BN, Chen GL, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism. Drug Metab Dispos. 2003;31:1255-1259.
2. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29:1102-1109.
3. Huezo-Diaz P, Perroud N, Spencer EP, et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol. 2012;26:398-407.
4. Rudberg I, Reubsaet JL, Hermann M, et al. Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro. Drug Metab Dispos. 2009;37:2340-2348.
5. Wang JH, Liu ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;70:42-47.
6. Rudberg I, Hermann M, Refsum H, et al. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol. 2008;64:1181-1188.
7. Ueda N, Yoshimura R, Umene-Nakano W, et al. Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J Biol Psychiatry. 2009;10:832-835.
8. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33:262-270.
9. Ko JW, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862.
10. Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827.
11. Frelinger AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59:1304-1311.
12. Gugler R, Hartmann M, Rudi J, et al. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol. 1996; 42:249-252.
13. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-718.
14. Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40:1698-1711.
15. Ogilvie BW, Yerino P, Kazmi F, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolismdependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011;39:2020-2033.
16. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60:287-290.
17. Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70:43-51.
18. Indiana University, School of Medicine, Division of Clinical Pharmacology. Cytochrome P450 drug interaction table. Available at: www.druginteractions. com. Accessed January 3, 2014.
19. Baxter K, ed. Stockley's Drug Interactions. 9th ed. London: The Pharmaceutical Press; 2010.
20. Machin D, Campbell MJ, Fayers PM, et al. Sample Size Tables for Clinical Studies, 2nd ed. Oxford: Blackwell Science; 1997.
21. Walsky RL, Astuccio AV, Obach RS. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006;46:1426-1438.
22. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 2007;68:1540-1545.
23. Waade RB, Molden E, Refsum H, et al. Serum concentrations of antidepressants in the elderly. Ther Drug Monit. 2012;34:25-30.
24. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999;55:177-184.
25. Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51:169-173.
26. European Medicines Agency. Escitalopram and risk of QT prolongation. Final SmPC and PL wording agreed by the PhVWP December 2011. Available at: http://www.hma.eu/fileadmin/dateien/Human-Medicines/CMD-h-/Product-Information/PhVWP-Recommendations/CMDhPhVW0442012-January12.pdf. Accessed January 3, 2014.
27. U.S. Food and Drug Administration. FDA Drug Safety Communication: revised recommendations for celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available at: http://www.fda.gov/drugs/drugsafety/ucm297391.htm. Accessed January 3, 2014.
28. Vieweg WVR, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med. 2012;125:859-868.
29. Hasnain M, Howland RH, Vieweg WVR. Escitalopram and QTc prolongation. J Psychiatry Neurosci. 2013;38:E11.
30. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry. 2000;61:594-599.